山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shandong Xinhua Pharmaceutical Company Limited (the "**Company**") has published the "Announcement on Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection having obtained Drug Registration Certificate" on CNINFO http://www.cninfo.com.cn (巨潮資訊網) on 4 April 2026. The English translation of the relevant document is hereby included for reference. If there is any inconsistency between the English version and the Chinese version, the Chinese version shall prevail.

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
He Tongqing
Chairman

7 April 2026 Zibo, PRC

As at the date of this announcement, the board of directors of the Company comprises:

Executive Directors:

Mr. He Tongqing *(Chairman)*
Mr. Xu Wenhui
Mr. Hou Ning

Non-executive Directors:

Mr. Zhang Chengyong

Independent Non-executive Directors:

Mr. Pan Guangcheng
Mr. Zhu Jianwei
Mr. Ling Peixue
Ms. Cheung Ching Ching, Daisy

Stock Code: 000756 Stock Short Name: Xinhua Pharmaceutical Announcement No.: 2026-20

Shandong Xinhua Pharmaceutical Company Limited

Announcement on Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection having obtained Drug Registration Certificate

The Company and its board of directors confirm that the contents of this announcement are true, accurate and complete without any false information, misleading statements or material omissions.

Shandong Xinhua Pharmaceutical Company Limited (hereinafter referred to as "Xinhua Pharmaceutical" or the "Company") has recently received the *Drug Registration Certificate* (药品注册证书) in connection with its Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection (hereinafter referred to as, the "**Product**") approved and issued by the National Medical Products Administration. Relevant information is now announced as follows:

I. Basic information

Drug name:	Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection
Dosage form:	Injection
Specifications:	20ml
Drug category:	Prescription drugs
Registered classification:	Class 3 chemicals
Applicant:	Shandong Xinhua Pharmaceutical Company Limited
Application matter:	Drug registration (Domestic production)
Case number:	CYHS2401763、CYHB2600135
Drug approval number:	National Medicine Zhunzi (国药准字) H20263780
Notification number:	2026S00929
Review conclusion:	In accordance with the Pharmaceutical Administration Law of the People's Republic of China (中华人民共和国药品管理法) and relevant regulation, upon review, the Product conforms with the applicable requirements of drug registration, the drug registration is approved, and the Drug Registration Certificate has been issued. The standard of quality, product instructions, labels as well as production processes concerning the Product shall be consummated in accordance with relevant documentation. Pharmaceutical production enterprises are required to meet requirements of pharmaceutical production quality management standards prior to the production and sale of drugs.

II. Other relevant information

In June 2024, Beijing Minkang Baicao Pharmaceutical Technology Company Limited (北京民康百草医药科技

有限公司)(hereinafter referred to as "Minkang Baicao") submitted application materials to the Center for Drug Evaluation of the State Drug Administration (药品审评中心) (CDE) concerning the marketing of Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection and the application materials were accepted.

In July 2024, Xinhua Pharmaceutical and Minkang Baicao signed a production technology and holder transfer contract. According to the contract, Minkang Baicao shall make a one-off transfer of all its Marketing Authorization Holder (MAH) rights (including, without limitation, formulation production approval and commercialization rights (including, but not limited to, those relating to product manufacturing, sales and marketing) to Xinhua Pharmaceutical. The total technology transfer fee shall be payable by Xinhua Pharmaceutical to Minkang Baicao in accordance with staged instalments as stipulated under the contract.

Pursuant to the Rules Governing the Listing of Shares on Shenzhen Stock Exchange (深圳证券交易所股票上市规则) and the articles of association of the Company (公司章程), the present transaction is not required to be submitted for the review and approval of the board of directors or shareholders' meeting of the Company. The present transaction does not constitute a related party transaction, nor does it constitute a significant asset restructuring as stipulated in the Measures for Administration of Material Assets Reorganization of Listed Companies (上市公司重大资产重组管理办法).

In January 2026, Xinhua Pharmaceutical submitted application materials to the Center for Drug Evaluation of the State Drug Administration (药品审评中心) (CDE) concerning the marketing of Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection and the application materials were accepted. In April 2026, Xinhua Pharmaceutical obtained the Drug Registration Certificate, and the review conclusion was that the Product shall be approved for registration.

The Product is suitable for electrolyte supplementation during central venous infusion of solutions containing concentrated glucose or amino acids to maintain electrolyte homeostasis in adult patients. The Product has not been imported from overseas. Domestic manufacturers are newly approved and have not yet launched large-scale commercial sales.

III. Impact on the Company and risk warning

The obtaining of *Drug Registration Cerrtificate* in connection with Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection by Xinhua Pharmaceutical in April 2026 will enrich the Company's pharmaceutical formulation product series and enhancing its competitiveness.

The pharmaceutical sales business is susceptible to changes in domestic pharmaceutical industry policies, bidding and procurement processes, changes in the market environment and other factors, and is subject to uncertainty. Investors are advised to invest sensibly and pay attention to investment risks.

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
3 April 2026